Compare BridgeBio Pharma Inc (BBIO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Consumer Staples Select Sector SPDR Fund trades at $84.55. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| BBIO | XLP | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $90.00 |
52-Week Low | $47.29 | $75.61 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
XLP trades at $85.12 with minimal daily movement (+0.01%). The ETF maintains a bullish technical outlook with strong moving average signals and oversold RSI conditions. Analyst consensus is unanimously positive with 100% buy ratings. Recent news highlights consumer staples sector resilience amid market uncertainty, with Coca-Cola's strong earnings demonstrating the defensive appeal of staple goods companies.
The defensive nature of consumer staples provides stability during market volatility, though limited financial ratio data requires deeper fundamental analysis. Key risks include sector rotation away from defensive plays and macroeconomic pressures on consumer spending. The 2.6% dividend yield offers income appeal for risk-averse investors seeking market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
